Impact of HLA Class I Antigen, Killer Inhibitory Receptor, and FCGR3A Genotypes on Breast Cancer Susceptibility and Tumor Stage.

Angelica Canossi Anna Aureli Tiziana Del Beato Giorgio Novelli Oreste Claudio BuonomoPiero RossiAdriano Venditti Franco Papola Giuseppe Sconocchia

Published in: Current molecular medicine (2023)

Our findings suggest that in the development of BC probably exists a disorder of the NK innate immunity influenced by KIR/HLA-C gene content and FCGR3A-158 polymorphisms and that the combined analysis of these biomarkers might help predict genetic risk scores for tailored screening of BC patients in therapy.

Keyphrases

end stage renal disease
genome wide
ejection fraction
chronic kidney disease
newly diagnosed
copy number
peritoneal dialysis
prognostic factors
gene expression
stem cells
patient reported outcomes
mesenchymal stem cells
smoking cessation
breast cancer risk